<?xml version='1.0' encoding='utf-8'?>
<document id="25469982"><sentence text="Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption."><entity charOffset="13-20" id="DDI-PubMed.25469982.s1.e0" text="MK-8970" /><entity charOffset="25-41" id="DDI-PubMed.25469982.s1.e1" text="acetal carbonate" /><entity charOffset="53-64" id="DDI-PubMed.25469982.s1.e2" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.25469982.s1.e0" e2="DDI-PubMed.25469982.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25469982.s1.e0" e2="DDI-PubMed.25469982.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25469982.s1.e0" e2="DDI-PubMed.25469982.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25469982.s1.e1" e2="DDI-PubMed.25469982.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25469982.s1.e1" e2="DDI-PubMed.25469982.s1.e2" /></sentence><sentence text="Developing new antiretroviral therapies for HIV-1 infection with potential for less frequent dosing represents an important goal within drug discovery" /><sentence text=" Herein, we present the discovery of ethyl (1-((4-((4-fluorobenzyl)carbamoyl)-1-methyl-2-(2-(5-methyl- 1,3,4-oxadiazole-2-carboxamido)propan-2-yl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)ethyl) carbonate (MK-8970), a highly optimized prodrug of raltegravir (Isentress)"><entity charOffset="37-199" id="DDI-PubMed.25469982.s3.e0" text="ethyl (1-((4-((4-fluorobenzyl)carbamoyl)-1-methyl-2-(2-(5-methyl- 1,3,4-oxadiazole-2-carboxamido)propan-2-yl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)ethyl) carbonate" /><entity charOffset="201-208" id="DDI-PubMed.25469982.s3.e1" text="MK-8970" /><entity charOffset="241-252" id="DDI-PubMed.25469982.s3.e2" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.25469982.s3.e0" e2="DDI-PubMed.25469982.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25469982.s3.e0" e2="DDI-PubMed.25469982.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25469982.s3.e0" e2="DDI-PubMed.25469982.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25469982.s3.e1" e2="DDI-PubMed.25469982.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25469982.s3.e1" e2="DDI-PubMed.25469982.s3.e2" /></sentence><sentence text=" Raltegravir is a small molecule HIV integrase strand-transfer inhibitor approved for the treatment of HIV infection with twice-daily administration"><entity charOffset="1-12" id="DDI-PubMed.25469982.s4.e0" text="Raltegravir" /></sentence><sentence text=" Two classes of prodrugs were designed to have enhanced colonic absorption, and derivatives were evaluated in pharmacokinetic studies, both in vitro and in vivo in different species, ultimately leading to the identification of MK-8970 as a suitable candidate for development as an HIV therapeutic with the potential to require less frequent administration while maintaining the favorable efficacy, tolerability, and minimal drug-drug interaction profile of raltegravir"><entity charOffset="457-468" id="DDI-PubMed.25469982.s5.e0" text="raltegravir" /></sentence><sentence text=" " /></document>